David Han

778 total citations
28 papers, 557 citations indexed

About

David Han is a scholar working on Infectious Diseases, Immunology and Molecular Biology. According to data from OpenAlex, David Han has authored 28 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 6 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in David Han's work include Antifungal resistance and susceptibility (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Computational Drug Discovery Methods (3 papers). David Han is often cited by papers focused on Antifungal resistance and susceptibility (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Computational Drug Discovery Methods (3 papers). David Han collaborates with scholars based in United States, United Kingdom and Japan. David Han's co-authors include Christopher Lademacher, Donna Kowalski, Takao Yamazaki, Amit Desai, Ronald Goldwater, Shahzad Akhtar, Robert Townsend, Kota Kato, Larry Ereshefsky and Muir Russell and has published in prestigious journals such as Circulation, The Journal of Clinical Endocrinology & Metabolism and Diabetes.

In The Last Decade

David Han

28 papers receiving 539 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Han United States	13	179	150	118	104	102	28	557
Ronald Goldwater United States	12	118 0.7×	190 1.3×	154 1.3×	90 0.9×	136 1.3×	32	708
Shu‐Pang Huang United States	13	162 0.9×	136 0.9×	121 1.0×	84 0.8×	111 1.1×	27	559
Haran Yogasundaram Canada	13	87 0.5×	126 0.8×	185 1.6×	37 0.4×	208 2.0×	31	768
Nicola E. Clarke United Kingdom	7	438 2.4×	49 0.3×	36 0.3×	81 0.8×	206 2.0×	8	881
Yoshinori Tsuchiyama Japan	8	58 0.3×	85 0.6×	113 1.0×	57 0.5×	235 2.3×	12	576
Carol Cronenberger United States	13	36 0.2×	44 0.3×	135 1.1×	101 1.0×	67 0.7×	28	540
Mark Allison United States	9	115 0.6×	81 0.5×	42 0.4×	65 0.6×	171 1.7×	14	514
Kristen Renee McSweeney Australia	6	116 0.6×	29 0.2×	43 0.4×	30 0.3×	182 1.8×	10	615
Vanessa Marchant Spain	12	82 0.5×	72 0.5×	52 0.4×	24 0.2×	244 2.4×	25	658
Mohammed Ullah United States	17	48 0.3×	64 0.4×	61 0.5×	30 0.3×	253 2.5×	24	807

Countries citing papers authored by David Han

Since Specialization

Citations

This map shows the geographic impact of David Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Han more than expected).

Fields of papers citing papers by David Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Han. The network helps show where David Han may publish in the future.

Co-authorship network of co-authors of David Han

This figure shows the co-authorship network connecting the top 25 collaborators of David Han. A scholar is included among the top collaborators of David Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Han. David Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taniuchi, Yuta, et al.. (2023). Single‐ and Multiple‐dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1128, a Novel Peroxisome Proliferator‐activated Receptor δ Modulator, in Healthy Participants. Clinical Pharmacology in Drug Development. 12(8). 810–818. 2 indexed citations

Nussbaum, Jesse C., Radha Railkar, Jeffrey R. Sachs, et al.. (2023). Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine. 41(44). 6488–6501. 12 indexed citations

Sharma, Shringi, Xavier Pépin, Jean Cheung, et al.. (2022). Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British Journal of Clinical Pharmacology. 88(10). 4573–4584. 3 indexed citations

Johansson, Susanne, David Han, Thomas R. Hunt, et al.. (2022). Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants. Pharmacology Research & Perspectives. 10(3). e00929–e00929. 5 indexed citations

Yin, Wei, David Han, Polyna Khudyakov, et al.. (2022). A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia. British Journal of Clinical Pharmacology. 88(8). 3872–3882. 10 indexed citations

Acevedo, Lisette M., Paramdeep Baweja, Kye Gilder, et al.. (2020). P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects. Journal of Crohn s and Colitis. 14(Supplement_1). S368–S368. 4 indexed citations

Nelander, Karin, Maria Lagerström‐Fermér, Erik Michaëlsson, et al.. (2020). Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction. Clinical and Translational Science. 14(3). 812–819. 25 indexed citations

Rege, Bhaskar, et al.. (2017). Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clinical Pharmacology in Drug Development. 7(2). 188–195. 33 indexed citations

Cebers, Gvido, Robert Alexander, Samantha Budd Haeberlein, et al.. (2016). AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease. Journal of Alzheimer s Disease. 55(3). 1039–1053. 68 indexed citations

10.

Zhu, Tong, Barbara A. Parker, Tetsuya Nishimura, et al.. (2016). Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects. Clinical Pharmacokinetics. 56(7). 747–757. 10 indexed citations

11.

Han, David, Carlos Fernández-Llatas, Eugene J. Sullivan, et al.. (2016). Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution. PA2398–PA2398. 3 indexed citations

12.

Yamazaki, Takao, Amit Desai, David Han, et al.. (2016). Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 93–101. 23 indexed citations

13.

Han, David, Carlos Fernández‐Peña, Eugene J. Sullivan, et al.. (2016). Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009). PA2403–PA2403. 6 indexed citations

14.

Yamazaki, Takao, Amit Desai, Ronald Goldwater, et al.. (2016). Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 54–65. 33 indexed citations

15.

Yamazaki, Takao, Amit Desai, Ronald Goldwater, et al.. (2016). Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 66–75. 42 indexed citations

16.

Groll, Andreas H., Amit Desai, David Han, et al.. (2016). Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Clinical Pharmacology in Drug Development. 6(1). 76–85. 103 indexed citations

17.

Martin, Paul, S.Y. Amy Cheung, Mark Yen, David Han, & Michael Gillen. (2015). Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies. European Journal of Clinical Pharmacology. 72(1). 61–71. 9 indexed citations

18.

Martinez, Jose A., et al.. (2014). Update of Retraction—Blockade of Receptor for Advanced Glycation End Products in a Model of Type 1 Diabetic Leukoencephalopathy. Diabetes. 19 November 2012 [Epub ahead of print]. DOI: 10.2337/db12-0317. Diabetes. 63(5). 1817–1817. 1 indexed citations

19.

Tseng, Jack, Marissa F. Dockendorf, Gopal Krishna, et al.. (2012). P1‐221: Safety and pharmacokinetics of the novel BACE inhibitor MK‐8931 in healthy subjects following single‐ and Multiple‐Dose administration. Alzheimer s & Dementia. 8(4S_Part_5). 3 indexed citations

20.

Forman, Mark S., John Palcza, Jack Tseng, et al.. (2012). P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration. Alzheimer s & Dementia. 8(4S_Part_19). 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact